Pfizer Told To Conduct Phase IV Trial of Abrocitinib in Indian Adolescents with Atopic Dermatitis
New Delhi: In a recent regulatory development, the Subject Expert Committee (SEC) under the Dermatology and Allergy division of the Central Drugs Standard Control Organisation (CDSCO) has recommended that Pfizer Products India Private Limited conduct a Phase IV clinical trial specifically in the adolescent population for its product Abrocitinib tablets 50 mg, 100 mg, and 200 mg.
The recommendation came after the firm sought a waiver to conduct an active surveillance study in lieu of the Phase IV trial for treating moderate-to-severe atopic dermatitis in patients aged 12 years and above.
The firm appeared before the committee during the SEC (Dermatology and Allergy) meeting held on June 11, 2025, in relation to its product Abrocitinib tablets 50 mg, 100 mg, and 200 mg, which are indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents aged 12 years and older who are candidates for systemic therapy.
Pfizer sought a waiver for Condition No. (X) to allow the conduct of an active surveillance study in lieu of a Phase IV clinical trial. The company informed the panel that this proposal had previously been discussed in the SEC meeting held on September 5, 2024, specifically for the adult population. At that time, the committee had already "opined to conduct the active surveillance study in adults population."
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.